Cystic Fibrosis

Cystic fibrosis is a life threatening, inherited disease of the exocrine glands. The condition primarily affects the digestive and respiratory systems which become clogged with a thick, sticky mucus. Cystic fibrosis is caused by a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene which results in an excess of salt and water passing into cells, causing a thick, sticky mucus to build up in bodily passageways.

Cystic Fibrosis (CF)

Cystic fibrosis is a genetic condition that affects the production and flow of mucus within the lungs and digestive system, parts of the body that then become clogged with a thick, sticky mucus.

Cystic Fibrosis Causes

Cystic Fibrosis Symptoms

Cystic Fibrosis Diagnosis

Cystic Fibrosis Treatment

Genetics of Cystic Fibrosis

Cystic Fibrosis Screening

Cystic Fibrosis Questions

Coping With Cystic Fibrosis

Cystic Fibrosis Facts

Cystic Fibrosis Epidemiology

Cystic Fibrosis Prognosis

See more featured articles »

Cystic Fibrosis Research

Could CRISPR Repair CFTR in Cystic Fibrosis Patients?

Sweat Test for Cystic Fibrosis

Cystic Fibrosis and Salty Skin

Cystic Fibrosis Evolution

Lung Transplantation for Cystic Fibrosis

Gene Therapy as a Potential Cure for Cystic Fibrosis

Cystic Fibrosis and Infertility

Cystic Fibrosis History

Tests for Cystic Fibrosis During Pregnancy

Latest Cystic Fibrosis News and Research

Air pollution and cold temperatures drive bronchiectasis mortality in vulnerable populations

Researchers investigate how short-term exposure to ambient air pollution and temperature affects bronchiectasis mortality rates in China.

26 Nov 2024

Enterprise Therapeutics publishes on medicinal chemistry of ETD001, a novel inhaled ENaC blocker for treatment of cystic fibrosis

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of people with respiratory diseases, today announced the publication of a peer reviewed study in The European Journal of Medicinal Chemistry.

From Enterprise Therapeutics Ltd 25 Nov 2024

Nanomedicine using gas bubbles offers hope for lung cancer treatment

The delivery of nanomedicines using gas bubbles has shown itself to be a unique way of transporting cytotoxins to the lungs of cancer patients.

22 Nov 2024

Study focuses on COPD progression in younger populations

Researchers are exploring how small airway abnormalities in younger smokers could help identify who is at risk of developing COPD and establish how the chronic lung disease progresses, according to a new article.

15 Nov 2024

Researchers make progress toward inhalable mRNA medicines

Most people don't enjoy getting shots for treatments or vaccines. So, researchers are working to create more medicines, such as those made from messenger RNA (mRNA), that can be sprayed and inhaled.

14 Nov 2024

Study provides new insights into the central role of goblet cells

In a recent study, researchers at the University of California, San Diego, have provided new insights into the central role of goblet cells-;specialized cells that line the gut-;in maintaining a healthy and balanced immune environment within the gastrointestinal (GI) tract.

12 Nov 2024

Artificial cilia system monitors mucus conditions in human airways

Xiaoguang Dong, assistant professor of mechanical engineering, is leading a team of researchers that has developed a system of artificial cilia capable of monitoring mucus conditions in human airways to better detect infection, airway obstruction, or the severity of diseases like Cystic Fibrosis (CF), Chronic Obstructive Pulmonary Diseases (COPD) and lung cancer.

7 Nov 2024

Yourgene Health Cystic Fibrosis Base assay receives IVDR accreditation

Yourgene Health (part of the Novacyt group of companies), a leading international molecular diagnostics group, announces that it has received accreditation under the new EU requirements of the in vitro diagnostic regulation (IVDR) for the Yourgene® Cystic Fibrosis Base assay. The Yourgene Cystic Fibrosis Base assay is a Class C in vitro medical device under IVDR and is intended for use by healthcare professionals within a molecular laboratory environment.

From Yourgene Health 28 Oct 2024

High-throughput imaging platform reveals impact of mutations on protein location

The team developed a high-throughput imaging platform to assess the influence of nearly 3,500 mutations on protein location. They found that roughly one in six disease-causing mutations led to proteins ending up in the wrong location in the cell.

26 Oct 2024

Unraveling the survival strategies of Pseudomonas aeruginosa in lung infections

Imagine trying to settle into a new home while constantly being attacked. That's what the bacterium Pseudomonas aeruginosa faces when it infects the lungs, and it can't both spread and protect itself from antibiotics at the same time.

25 Oct 2024

Study reveals resistance of Pseudomonas aeruginosa to common cleaning agents

A new study reveals widespread resistance of a major bacterial pathogen to the active ingredients in cleaning agents commonly used in hospitals and homes.

25 Oct 2024

Structural biology reveals secrets of DEV phage infection

The viruses that infect bacteria are the most abundant biological entities on the planet. For example, a recent simple study of 92 showerheads and 36 toothbrushes from American bathrooms found more than 600 types of bacterial viruses, commonly called bacteriophages or phages.

22 Oct 2024

Revealing the hidden role of blood leaks in Alzheimer’s and MS

The question of what causes complex neurological diseases such as Alzheimer's or multiple sclerosis continues to confound scientists and doctors, with the unknowns standing in the way of early diagnoses and effective treatments.

18 Oct 2024

Researchers awarded $7 million to innovate probiotic treatments for lung infections

University of California San Diego and University of California Berkeley researchers have been awarded up to $7 million from the Advanced Research Projects Agency for Health (ARPA-H) to conduct research under the PROTECT project -; Pro/Prebiotic Regulation for Optimized Treatment and Eradication of Clinical Threats.

10 Oct 2024

Vitamin B12 boosts testosterone levels in men with infertility

Research finds that higher serum vitamin B12 levels are associated with improved testosterone concentrations in men with infertility, but no impact on other reproductive hormones.

30 Sep 2024

Antiviral drug molnupiravir linked to new mutations in SARS-CoV-2

Molnupiravir, an antiviral drug used to treat patients with COVID-19, appears to be driving SARS-CoV-2 to mutate and evolve, with some of these new viruses being transmitted onwards, a new study has shown.

26 Sep 2024

Research reveals key role of mucin modification in muco-obstructive diseases

With each breath, a human may inhale thousands of harmful microbes into the lungs. Mucus, the gel-like moist substance coating the airways, is one of the first lines of defense and aids in removal these microbes.

24 Sep 2024

Early intervention key for mental health in children with cystic fibrosis

A University at Buffalo psychiatrist who has played a critical role in getting mental health screening and treatment integrated into routine care for adults and adolescents with cystic fibrosis (CF) has been awarded $3 million from the Cystic Fibrosis Foundation to focus on the mental health of children with the disease.

19 Sep 2024

Shorter leukocyte telomere length and greater LTL attrition tied to cystic fibrosis severity

A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science), Volume 16, Issue 16 on August 29, 2024, entitled, "Leukocyte telomere length and attrition in association with disease severity in cystic fibrosis patients."

12 Sep 2024

SP-101 gene therapy shows promise for cystic fibrosis treatment

Scientists from Spirovant Sciences describe SP-101, a novel adeno-associated virus (AAV) gene therapy for the treatment of cystic fibrosis (CF) in the peer-reviewed journal Human Gene Therapy.

9 Sep 2024